Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
HER2 acts an oncogenic driver in numerous cancers. Here, the authors design an anti-HER2 biparatopic and tetravalent IgG fusion with inhibitory effects in a xenograft model.
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-06-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-021-23948-6 |
| id |
doaj-bbc4cba63fcc425a86335df0941f73d7 |
|---|---|
| record_format |
Article |
| spelling |
doaj-bbc4cba63fcc425a86335df0941f73d72021-06-20T11:13:09ZengNature Publishing GroupNature Communications2041-17232021-06-0112111810.1038/s41467-021-23948-6Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of actionFlorian Kast0Martin Schwill1Jakob C. Stüber2Svende Pfundstein3Gabriela Nagy-Davidescu4Josep M. Monné Rodríguez5Frauke Seehusen6Christian P. Richter7Annemarie Honegger8Karen Patricia Hartmann9Thomas G. Weber10Felix Kroener11Patrick Ernst12Jacob Piehler13Andreas Plückthun14Department of Biochemistry, University of ZurichDepartment of Biochemistry, University of ZurichDepartment of Biochemistry, University of ZurichDepartment of Biochemistry, University of ZurichDepartment of Biochemistry, University of ZurichLaboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of ZurichLaboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of ZurichDepartment of Biology/Chemistry and Center for Cellular Nanoanalytics, Osnabrück UniversityDepartment of Biochemistry, University of ZurichDepartment of Biochemistry, University of ZurichDynamic Biosensors GmbHDynamic Biosensors GmbHDepartment of Biochemistry, University of ZurichDepartment of Biology/Chemistry and Center for Cellular Nanoanalytics, Osnabrück UniversityDepartment of Biochemistry, University of ZurichHER2 acts an oncogenic driver in numerous cancers. Here, the authors design an anti-HER2 biparatopic and tetravalent IgG fusion with inhibitory effects in a xenograft model.https://doi.org/10.1038/s41467-021-23948-6 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Florian Kast Martin Schwill Jakob C. Stüber Svende Pfundstein Gabriela Nagy-Davidescu Josep M. Monné Rodríguez Frauke Seehusen Christian P. Richter Annemarie Honegger Karen Patricia Hartmann Thomas G. Weber Felix Kroener Patrick Ernst Jacob Piehler Andreas Plückthun |
| spellingShingle |
Florian Kast Martin Schwill Jakob C. Stüber Svende Pfundstein Gabriela Nagy-Davidescu Josep M. Monné Rodríguez Frauke Seehusen Christian P. Richter Annemarie Honegger Karen Patricia Hartmann Thomas G. Weber Felix Kroener Patrick Ernst Jacob Piehler Andreas Plückthun Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action Nature Communications |
| author_facet |
Florian Kast Martin Schwill Jakob C. Stüber Svende Pfundstein Gabriela Nagy-Davidescu Josep M. Monné Rodríguez Frauke Seehusen Christian P. Richter Annemarie Honegger Karen Patricia Hartmann Thomas G. Weber Felix Kroener Patrick Ernst Jacob Piehler Andreas Plückthun |
| author_sort |
Florian Kast |
| title |
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action |
| title_short |
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action |
| title_full |
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action |
| title_fullStr |
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action |
| title_full_unstemmed |
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action |
| title_sort |
engineering an anti-her2 biparatopic antibody with a multimodal mechanism of action |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2021-06-01 |
| description |
HER2 acts an oncogenic driver in numerous cancers. Here, the authors design an anti-HER2 biparatopic and tetravalent IgG fusion with inhibitory effects in a xenograft model. |
| url |
https://doi.org/10.1038/s41467-021-23948-6 |
| work_keys_str_mv |
AT floriankast engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT martinschwill engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT jakobcstuber engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT svendepfundstein engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT gabrielanagydavidescu engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT josepmmonnerodriguez engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT fraukeseehusen engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT christianprichter engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT annemariehonegger engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT karenpatriciahartmann engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT thomasgweber engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT felixkroener engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT patrickernst engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT jacobpiehler engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT andreaspluckthun engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction |
| _version_ |
1721370373982781440 |